[Preclinical in vitro and in vivo models for the assessment of biological activity in biosimilarity studies]. / Modelos preclínicos in vitro e in vivo para la evaluación de la actividad biológica en estudios de biocomparabilidad.
Gac Med Mex
; 151(3): 377-86, 2015.
Article
em Es
| MEDLINE
| ID: mdl-26089274
A drug that contains a recombinant protein as an active principle is called a biotechnological drug or biopharmaceutical.There are currently over 300 biopharmaceuticals worldwide. Many of these contains a similar active principle (biosimilar drug) as other previously registered (innovator drug). It has suggested that due to the complex implications in a formulation containing a protein, the manufacturing process is a key factor for efficacy and safety requirements. In fact, certain variability has been detected of the protein properties in different lots (or batches) of the same manufacturer, which produce changes at a clinical level. For this reason, the evaluation of biosimilar drugs has acquired great relevance, being the preclinical level of one of the more important stages of the development due to its lower cost (with respect to the clinical level) and its high capacity to detect formulation-manufacture problems. However, the demonstration of comparability at physicochemical, preclinical, and clinical levels is required in order to achieve market registration. In this review the in vitro and in vivo models used for the assessment of proposed biosimilars will be discussed.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Medicamentos Biossimilares
/
Modelos Biológicos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
Es
Revista:
Gac Med Mex
Ano de publicação:
2015
Tipo de documento:
Article
País de publicação:
México